Codiak, page-3

Codiak essentially 'gave away' their manufacturing capacity for a 'set amount' of manufacturing work. on one view this could be interpreted at favourable to EX1, which a central tenant of their development is the ability to mass produce exosomes. in general a lot of the US biotech sector seems to have taken a decline, just probably a desire for people to seek security and move away from high risk / high return, but it's not universal across all companies. I have been researching for bargains in the biotech Nasdaq space
CDAK has had some positive efficacy signals in current trials and they are commencing new trials. so still very active. some interesting comments in the webinars from scientists regarding efficacy signals. i have purchased some CDAK and follow them closely. I think EX1 is the forerunner for manufacturing exosomes as the medicines start to be developed. some very fascinating studies and data released every week regarding potential uses ect from universities. all comments are just IMHO